Core Insights - Three stocks with strong momentum and buy rankings are highlighted for investors: Gold Fields Limited, Genmab, and Aegon [1][2][3]. Group 1: Gold Fields Limited (GFI) - Gold Fields Limited is one of the world's largest unhedged gold producers with operations in South Africa, Ghana, and Australia [1]. - The company has a Zacks Rank 1 (Strong Buy) and its current year earnings estimate increased by 7% over the last 60 days [1]. - Gold Fields' shares gained 76.1% over the last three months, significantly outperforming the S&P 500's gain of 7% [2]. - The company possesses a Momentum Score of A [2]. Group 2: Genmab (GMAB) - Genmab is a biotechnology company specializing in antibody therapeutics for cancer treatment [2]. - The company also has a Zacks Rank 1 and its current year earnings estimate increased by 10.1% over the last 60 days [2][3]. - Genmab's shares gained 58.2% over the last three months, again outperforming the S&P 500's gain of 7% [3]. - The company possesses a Momentum Score of A [3]. Group 3: Aegon (AEG) - Aegon is an international insurance group providing life and health insurance, as well as pension, savings, and investment products in Europe, North America, and the Caribbean [3][4]. - The company has a Zacks Rank 1 and its current year earnings estimate increased by 10.1% over the last 60 days [3][4]. - Aegon's shares gained 11.1% over the last three months, outperforming the S&P 500's gain of 7% [4]. - The company possesses a Momentum Score of A [4].

Group 1 - The article highlights the challenges faced by Sarepta Therapeutics, Inc. in 2025, indicating it has been a particularly difficult year for the company [1] - The investing group Haggerston BioHealth offers insights for both novice and experienced biotech investors, including catalysts to watch and buy/sell ratings [2] - The group provides detailed financial analyses, including product sales forecasts and integrated financial statements for major pharmaceutical companies [2]

Core Insights - ALX Oncology is set to present updated data from its Phase 2 ASPEN-06 trial, focusing on evorpacept as a treatment for HER2-positive gastric cancer, at the SITC 40th Annual Meeting in November 2025 [1][2] - The trial evaluates evorpacept in combination with HERCEPTIN, CYRAMZA, and paclitaxel for patients with advanced gastric cancer who have previously undergone treatment [1][3] Company Overview - ALX Oncology is a clinical-stage biotechnology company dedicated to developing novel cancer therapies aimed at extending patient lives [4] - The lead candidate, evorpacept, is being assessed in various clinical trials across multiple cancer indications, indicating its potential as a cornerstone therapy in immuno-oncology [4] - The second pipeline candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate that began Phase 1 trials in August 2025 [4]

Core Insights - BioAtla, Inc. is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][4] - The company will present clinical data for its AXL-targeting antibody-drug conjugate, mecbotamab vedotin (BA3011), at the SITC 2025 Annual Meeting [1][2] Presentation Details - The presentation titled "Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC" will be delivered by Dr. Mihaela Druta [2] - The abstract (523) will be featured in the poster session, with the specific presentation time to be announced [2] Company Overview - BioAtla operates in San Diego, California, and Beijing, China, through a partnership with BioDuro-Sundia for preclinical development services [4] - The company utilizes its proprietary CAB platform technology to develop novel monoclonal and bispecific antibodies, aiming for selective targeting, greater efficacy, and lower toxicity [4] - BioAtla holds extensive patent coverage for its CAB platform technology, with over 780 active patent matters, including more than 500 issued patents [4]

Group 1: Market Overview - Global equity markets reported positive returns in Q2 2025, driven by U.S. trade deals and expected fiscal stimulus in Europe, which countered tariff challenges and geopolitical tensions [1] - The Clearbridge Global Value Improvers Strategy outperformed the benchmark MSCI World Value Index in the quarter, with strong contributions from industrials and IT holdings [1] Group 2: Corcept Therapeutics Incorporated - Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biotechnology company focused on developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders [2] - The stock of Corcept Therapeutics saw a one-month return of 23.24% and an impressive 88.16% increase over the last 52 weeks, closing at $85.48 per share with a market capitalization of $9.01 billion on October 2, 2025 [2] - Portfolio activity for the Clearbridge Global Value Improvers Strategy included exiting Uber Technologies and adding Corcept Therapeutics, which specializes in cortisol management with broader implications than previously understood [3] Group 3: Financial Performance - Corcept Therapeutics reported revenue of $194.4 million in Q2 2025, an increase from $163.8 million in Q2 2024 [4] - Despite the potential of Corcept as an investment, certain AI stocks are considered to offer greater upside potential and less downside risk [4]

AI Industry Insights - OpenAI's ChatGPT has significantly influenced the future of work since its launch nearly three years ago, with global AI spending projected to reach nearly $1.5 trillion in 2025 and surpass $2 trillion in 2026, driven by integration into various technologies [1][2] - Major tech companies such as OpenAI, Anthropic, Google, Microsoft, and Meta are benefiting from the ongoing AI boom, although some companies are reassessing their AI strategies after a period of overhyped expectations [1][2] - A "vibe shift" in the AI landscape is acknowledged, but experts do not foresee a repeat of the late-1990s tech bust, emphasizing that AI continues to drive transformation and the emergence of new business models [3][4] AI Integration and Usage - AI is evolving from being a rising star to an ambient operator that influences organizational processes, products, and decisions, akin to electricity in daily life [4] - Verizon's CFO, Tony Skiadas, highlights the importance of developing innovative AI use cases and shares personal experiences of using AI for tasks like report summarization, emphasizing its role as a time saver [5][6] AI Value Gap - A report by Boston Consulting Group indicates that the performance gap between AI leaders and laggards is widening, with agentic AI expected to account for 17% of total AI value in 2025, rising to 29% by 2028 [14]

Core Insights - BriaCell Therapeutics Corp. will present preclinical data on Bria-OTS+ at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting from November 7-9, 2025 [1][2] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [3]

The CNBC app, global market news in one place. Customizable sections and personalized alerts. Stocks tracking, interactive charts and market insights, all in your hands.Stay connected, stay informed. Download the CNBC app today. Ah, it's my favorite Friday of the month.Payroll. Hang on a second. Oh, there's no payroll.Dang. Anyway, it's still Squadbox Europe and you still have Karen Cho and Juliana Tattlebalm. And yes, despite the shutdown, Steve Sedick is still here.I know it's a shame. These are your head ...

Core Insights - Datavault AI Inc. has successfully converted long-term notes with an original face value of $13.3 million, significantly strengthening its balance sheet [1][2] - The conversion of these notes is viewed as a strategic milestone that supports the accelerated launch of independent data exchanges (IDEs) and the development of supercomputing capabilities in collaboration with IBM [2] - The company recently secured a $150 million strategic equity investment in Bitcoin from Scilex, a Nasdaq-listed biotech company, which aligns with Datavault AI's focus on the biotech sector as a primary target market [2] Company Overview - Datavault AI is a leader in AI-driven data experiences, focusing on the valuation and monetization of assets within the Web 3.0 environment [3] - The company's cloud-based platform offers comprehensive solutions across various industries, including sports & entertainment, biotech, education, fintech, real estate, healthcare, and energy [3] - Datavault AI's technology suite includes patented technologies for audio transmission and high-performance computing solutions for data perception, valuation, and secure monetization [3] - The Information Data Exchange (IDE) enables the creation of Digital Twins and the licensing of name, image, and likeness (NIL), promoting responsible AI practices [3]

ClearPoint Neuro's (NASDAQ: CLPT ) share price recently surged on the back of uniQure's ( QURE ) extremely strong Huntington's data. While the financial impact of AMT-130 should be meaningful, the data is more important as confirmatory evidence of the strength of ClearPoint’sRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can b ...